Despite this considerable and promising clinical experience, there is concern about the possible toxicity of ketamine when applied next to neural structures. Ketamine, S(+)-ketamine, and other NMDA antagonists have been shown to induce neurotoxicity when applied intrathecally over days and weeks. 3 -5 Applied intrathecally, ketamine damages the white and grey matter of the spinal cord, most lesions being found subpial and around the spinal canal in animal models and patients. Surprisingly, neither animals nor patients had any detectable loss of function. Histopathologically, signs of chromatolysis were detected after long-term application of preservative-free ketamine. 5 6 These lesions were recognized as possible retrograde degeneration after a distal axonal lesion or widespread demyelination. Chromatolysis can possibly be a late sign of apoptosis, that is, programmed cell death, but so far the mechanism of local toxicity induced by ketamine is unknown. Apoptosis is regulated by a cascade of specialized proteases called caspases. Caspase-3 is activated late in the apoptosis cascade, whereas caspase-8 and caspase-9 are activated at an early stage of apoptosis. Caspase-9 is the central caspase of the mitochondrial signalling pathway, whereas caspase-8 is essential for death receptor-induced apoptosis. Both pathways converge at the activation of caspase-3 which cleaves more downstream effectors, finally leading to the typical morphological alterations of apoptosis. 7 The pathways of apoptosis are delineated in a simplified scheme in Figure 1 . The mitochondrial pathway of apoptosis is activated by permeabilization of the outer mitochondrial membrane. After permeabilization several apoptogenic factors are released from the mitochondrial intermembrane space, for example, cytochrome c. Cytochrome c together with caspase-9 induces the formation of the apoptosome, a high-molecular-weight complex, which then activates caspase-3 and therewith the common pathway of apoptosis. 7 The extrinsic pathway is activated by death receptors. These are specialized cell-surface receptors including Fas/CD95 and tumour necrosis factor-a-related apoptosisinducing ligand receptors. Activation of this pathway induces the formation of the death-inducing signal complex including Fas-associated protein with death domain (FADD) which then leads via activation of caspase-8 to cleavage of caspase-3 and induction of the common pathway of apoptosis. 7 To study the mechanism of ketamine toxicity on a cellular and subcellular level, non-neuronal and neuronal cell lines expressing the NMDA receptor were investigated. We first evaluated, using different methods, whether ketamine induces apoptosis. In a lymphoma cell line with genetically modified pathways of apoptosis, we determined whether ketamine-induced apoptosis is mediated via the mitochondrial or the death receptor pathway. In neuroblastoma cells, the effect of a caspase inhibitor on ketamine-induced cell death was studied. In neuronal cells, the stereospecific effects of ketamine were elucidated by comparing the apoptosis induced by S(+)-ketamine when compared with its racemate. Finally, we analysed the apoptosis induced by incubation (5 days) with ketamine in neuroblastoma cells.
Methods
All experiments were performed at the laboratory of the Department of Anaesthesiology of the University of Dü sseldorf.
Reagents
Ketamine and S(+)-ketamine were purchased from Sigma Aldrich (St Louis, MO, USA) as a pure hydrochloride salt without preservatives. The pancaspase inhibitor Q-VD was purchased from Calbiochem (San Diego, CA, USA). The fluorescent probe Annexin V -FITC conjugate and the FITC-labelled anti-caspase-3 antibody were obtained from BD Biosciences (San Diego, CA, USA). The NMDA receptor 1-antibody and the rabbit polyclonal anti-caspase-3 antibody were purchased from Cell Signaling (Cell Signaling Technology/New England Biolabs GmbH, Frankfurt am Main, Germany). A goat anti-rabbit IgG conjugated to horseradish peroxidase was used as a secondary antibody (Dianova, Hamburg, Germany). XTT sodium salt was purchased from Sigma Aldrich. Phosphate-buffered saline (PBS) without calcium and magnesium was obtained from Gibco and Invitrogen (Carlsbad, CA, USA). Trypsin/EDTA was purchased from Biochrom AG (Berlin, Germany). Reagents not mentioned above were purchased from Sigma Aldrich.
Cell culture
Jurkat cells stably overexpressing B-cell-lymphoma 2 protein (Bcl-2) and the corresponding wild-type cells (clone J16) have been described before. 8 Caspase-9-deficient (clone JMR) and -proficient Jurkat cells have been characterized before. 9 10 John Blenis, PhD (Department of Cell Biology, Harvard Medical School, Boston, MA, USA), kindly provided FADDand caspase-8-deficient Jurkat cells and the parental cell line (clone A3). The characteristics and origin of human SHEP neuroblastoma cells have been described before. 7 11 Rosswell Park Memorial Institute (RPMI) 1640 medium, supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 U ml 21 penicillin, and 50 mg ml 21 streptomycin, was used as the culture medium for all cell lines. Cells were cultured in a humidified atmosphere containing 5% carbon dioxide at 378C. 
Exposure to ketamine and S(1)-ketamine and experimental protocol
In order to allow logarithmic growth, Jurkat and neuroblastoma (SHEP) cells were cultured overnight in a complete medium at a concentration of 4×10 5 cells/ml. Subsequently, cells were cultured with fresh medium alone (as a negative control), with the proapoptotic kinase inhibitor staurosporine (STS) (as a positive control), or with indicated concentrations of racemic ketamine or S(+)-ketamine. When indicated, the pancaspase inhibitor Q-VD (10 mM) was added to cell cultures 1 h before the addition of ketamine. 
Detection of early apoptosis

Detection of caspase-3 activity
Caspase-3 is one of the key proteases in early apoptosis. To determine caspase-3 activity after incubation with ketamine, the cells were fixed with 4% paraformaldehyde, washed twice with PBS, and incubated with 3% bovine serum albumin (BSA), 0.05% Saponin in PBS, and 20 ml of the FITC-labelled anti-caspase-3 antibody for 1 h protected against light. Next, cells were washed once with PBS supplemented with 2% BSA, resuspended in PBS, and analysed flowcytometrically.
Details regarding detection of mitochondrial metabolic activity and western blot analysis are given in the Supplementary material.
Statistical analysis
All experiments were performed at least in triplicates. Results are expressed as mean (SD). All calculations were performed with the SPSS program version 16.0 (SPSS Inc., Chicago, IL, USA). Comparisons between groups were made by the MannWhitney U-test. A value of P,0.05 was considered significant.
Results
Western blot analysis revealed that T-lymphoma cells (Jurkat) and human neuroblastoma cells (SHEP) expressed the NMDA receptor 1 (see Supplementary Fig. S1 ).
Jurkat T-lymphoma cells were investigated for the percentage of early apoptotic and late apoptotic or necrotic cell death after 24 h treatment with ketamine. Flowcytometric analysis revealed a concentration-dependent toxicity of ketamine at millimolar concentrations leading to early apoptotic (Annexin V-positive/7-AAD-negative) and late apoptotic or necrotic (Annexin V-positive/7-AAD-positive) cell death ( Fig. 2A) . Thus, 3 mM ketamine induced 65.9 (5.1)% cell death, whereas the negative control only had a percentage of 5.9 (1.3)% and the positive control (STS) a percentage of 86.9 (2.6)% cell death (P,0.05).
In order to determine possible involvement of the mitochondrial pathway of apoptosis in ketamine-induced apoptosis, Jurkat cell clones either overexpressing Bcl-2 or deficient for caspase-9 were exposed to ketamine. These genetically engineered cell lines with an altered mitochondrial pathway of apoptosis were protected against the apoptosis-inducing effects of ketamine (Fig. 2B) . Two millimolars of ketamine induced 43.2 (1.9)% cell death in wild-type cells but led only to 11.0 (2.9)% cell death in cells overexpressing Bcl-2. Interestingly, cells deficient in caspase-9 were completely protected [4.1 (0.6)% cell death] against the apoptosis-inducing effect of ketamine at the same concentration (Fig. 2B) . Thus, inhibition of the mitochondrial pathway of apoptosis protected to a considerable extent against ketamine-induced apoptosis. The influence of the death receptor pathway of apoptosis was investigated in Jurkat cell lines deficient of caspase-8 and FADD, an intracellular adapter molecule of the death receptor. Caspase-8-deficient cells and FADD-deficient cells were not significantly protected against ketamine toxicity (Fig. 2C) . Thus, ketamine induces cell death via the mitochondrial pathway without significant death receptor signalling.
As a model of cells of neuroectodermal origin, we investigated neuroblastoma cells. As in Jurkat cells, apoptosis and overall cell death were analysed by flow cytometry in SHEP neuroblastoma cells exposed 24 h to increasing concentrations of ketamine (see Supplementary Fig. S2 ). Ketamine induced concentration-dependent toxicity between 2 and 8 mM (Fig. 3A) . At 2 and 4 mM, the percentage of cells undergoing early apoptosis (Annexin V-positive/7-AAD-negative) was 9.4 (3.0)% and 14.2 (0.1)%, respectively, whereas with 6 and 8 mM ketamine induced only 8.0 (2.2)% and 2.6 (0.3)%, respectively. These results were verified by analysing caspase-3 activity after treatment of cells with different ketamine concentrations (Fig. 3B ). Caspase-3 activity increased after treatment with 2 mM [4.6 (0.8)%] to 8 mM ketamine [35.2 (7.4)%], whereas 12 mM led to a decrease in caspase-3 activity [11.1 (3.3)%]. These results were confirmed by immunoblotting (see Supplementary Fig. S3 ).
The pancaspase inhibitor (Q-VD) reduced the percentage of cell death induced by 4 mM ketamine from 45.9 (2.4)% to 8.2 (1.9)% (P,0.05). The relative effect size of Q-VD was less at greater concentrations (Fig. 4) . Thus , and caspase-9-deficient (cas92) cells were exposed to control medium (left) or 2 mM ketamine (right).
(C) Wilde-type (wt), caspase-8-deficient (cas82), and FADD-deficient (FADD2) cells were exposed to the control medium (left) or 2 mM ketamine (right). Data are presented as mean (SD). *P,0.05 compared with the negative control; n.s., not significant (n¼3).
at low concentrations predominantly induced apoptosis, whereas at higher concentrations, necrosis predominated. Next, we investigated whether the same toxic effects occur with lower concentrations and longer exposure times. Thus, neuroblastoma cells were exposed for up to 120 h to various concentrations of ketamine. The lowest concentration inducing a significant reduction in mitochondrial activity and thus viability of the cells was 400 mM, reducing mitochondrial activity by 14.9 (4.3)% (P,0.01). This effect was concentration-dependent, with a maximum reduction of mitochondrial activity of 39.4 (6.5)% at 1600 mM (P,0.001; for detail, see Supplementary  Fig. S4 ). Thus, the toxicity of ketamine depends not only on the concentration, but also on exposure time.
In order to investigate whether the observed toxicity may be related to a stereospecific effect of ketamine on the NMDA receptor, we compared racemic ketamine with its enantiomer S(+)-ketamine in Jurkat cells, and in neuroblastoma cells, by means of Annexin V/7-AAD flow cytometry. In Jurkat cells, S(+)-ketamine and the racemate induced exactly the same toxicity (Fig. 5A) , whereas in neuroblastoma cells, S(+)-ketamine was slightly less toxic than the racemate (Fig. 5B) . The difference in effect of the enantiomers was rather small. The maximum difference in cell death was observed at a concentration of 2 mM. At this concentration, S(+)-ketamine induced 9.1 (0.6)% cell death, whereas racemic ketamine induced 18.3 (12.4)% cell death (P,0.05).
Discussion
Our results indicate that ketamine at low millimolar concentrations induces apoptosis in non-neuronal and neuronal cells, whereas higher concentrations predominantly lead to necrosis. Apoptosis induction by ketamine is mediated via the mitochondrial pathway and independent of death receptor signalling. Ketamine-induced apoptosis is concentrationand time-dependent and can be almost completely prevented by caspase inhibition. Finally, the apoptosis-inducing effect of ketamine is not or is only marginally stereospecific, making an involvement of the NMDA receptor unlikely. Although the potential neurotoxicity of ketamine after application close to neural structures has been discussed, 3 the preservative chlorobutanol was identified as the main toxic agent after single application. 12 Nevertheless, after repeated applications, even preservative-free ketamine displayed at least morphological damage, whereas alterations in nerve function were not investigated systematically. 13 Recently, it has been demonstrated that preservative-free S(+)-ketamine applied intrathecally in rabbits also leads to severe histopathological damage without any functional deficits. 5 Similar histopathological results, but without functional neurological deficit, have been described after long-term intrathecal application of ketamine in case reports of patients with otherwise unbearable pain. 6 14 The locations of the lesions induced by ketamine have been described in detail and are predominantly subependymal and around the central canal, where presumably the neural structures were exposed to the highest concentrations of ketamine. The morphological features are most frequently reported in terms of demyelination and necrosis. Recently, chromatolysis has been found after intrathecal application of ketamine. 5 Chromatolysis is a late, but not pathognomonic, morphological sign of apoptosis. In our in vitro model, we demonstrated that ketamine concentration-and time-dependently induces apoptosis and, at higher concentrations, necrosis. Thus, the caspase-3 activity first increased concentration-dependently and decreased with the highest concentrations tested (Fig. 3B) , although the overall toxicity increased further with higher concentrations (Figs 3A and 4) . Furthermore, the protective effect of a caspase inhibitor diminished also with higher concentrations (Fig. 4) . So, the mechanism of cell death changes with increasing concentrations from apoptosis to necrosis. This phenomenon is not unusual, for example, the same effect is also seen with the local anaesthetic lidocaine. 7 Similar to findings using lidocaine, our results indicate that apoptosis induced by ketamine is mediated via the mitochondrial pathway and is independent of death receptor signalling. Yon and colleagues 15 showed that apoptosis induced by systemic application of ketamine in neonatal rats is mediated via the mitochondrial and the death receptor pathway. That appears to contradict the results presented here, but the presumable plasma concentrations of ketamine reached in neonatal animals are certainly far below those occurring after local application. Furthermore, in the neonatal animals, ketamine when given systemically induces neuroapoptosis via the NMDA receptor 1, 16 whereas in our model, it seems independent of NMDA receptor. But the neurotoxic effects of ketamine observed in neonatal neurons have another pathomechansim, since they are mediated via the NMDA receptor and are induced with concentration about a hundred times lower than in our model. Our results were observed in dedifferentiated tumour cells and not during the physiological spurt of apoptosis and synaptogenesis as in neonatal animal models. Thus, the pathway of toxicity revealed here is presumably different from the apoptosis seen in the brain after systemic application of general anaesthetics. Interestingly, Lee and colleagues 17 found that in human hepatoma cell cultures, ketamine also in millimolar concentrations induced incorporation of Bax proteins into the mitochondrial membrane, cytochrome c release, caspase activation, and finally apoptosis. Thus, also in these non-neuronal cells, ketamine induced apoptosis via the mitochondrial pathway. The difference in toxicity of the ketamine enantiomers in neuroblastoma cells was-although significant-fairly minor. Presumably, this does not reflect the several-fold difference in potency at the phencyclidine-binding site of the NMDA receptor. 18 Thus, the local toxicity of ketamine observed here is unlikely to be mediated via the NMDA receptor. Clinically, ketamine is used epidurally in combination with an opioid or a local anaesthetic at concentrations around 0.4 mg ml 21 (≈1.5 mM) over several days. 19 -24 In patients with chronic pain, it has been used intrathecally at concentrations up to 25 mg ml 21 (≈93 mM) over weeks and months. 6 25 26 Unfortunately, ketamine concentrations occurring epidurally or intrathecally during these applications are not known. Nevertheless, in clinical practice, ketamine is administered intrathecally at concentrations about a hundred times greater than those already inducing significant toxicity in our in vitro model.
However, the results presented should not be extrapolated to the clinical situation. Nevertheless, it is important to know that ketamine and lidocaine (and other local anaesthetics) induce apoptosis via the same mitochondrial pathway. 7 11 Thus, an additive effect might be presumed when they are used in combination.
However, all available evidence from in vitro, in vivo, and patient studies suggests that caution and good clinical judgement are warranted when applying high concentrations of ketamine intrathecally or epidurally over a long period of time. More safety studies should be performed so that the margin of safety for the use of neuraxially administered ketamine can be definitively determined. In conclusion, ketamine concentration-and timedependently induces apoptosis and necrosis in vitro. Apoptosis is induced via the mitochondrial pathway, independent of death receptor signalling. This toxicity is not or only minimally stereoselective and therefore unlikely to be mediated via the NMDA receptor.
Supplementary material
Supplementary material is available at British Journal of Anaesthesia online.
